切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2019, Vol. 13 ›› Issue (01) : 65 -68. doi: 10.3877/cma.j.issn.1674-3946.2019.01.021

所属专题: 文献

论著

外周血SEPT9基因甲基化检测在结直肠癌筛查及术后随访中的意义分析
石会勇1,(), 赵春红2, 甄亚男1, 霍守俊1, 王若谷1   
  1. 1. 250031 山东临邑,山东省医学科学院附属医院胃肠外科
    2. 250031 山东临邑,山东省医学科学院附属医院中心实验室
  • 收稿日期:2018-02-23 出版日期:2019-02-26
  • 通信作者: 石会勇

Analysis of SEPT9 gene methylation in diagnosis and follow-up of colorectal cancer

Huiyong Shi1,(), Chunhong Zhao2, Yanan Zhen1, Shoujun Huo1, Ruogu Wang1   

  1. 1. Department of Gastrointestinal Surgery, Affiliated Hospital of Shandong Academy of Medical Sciences, Linyi Shandong 250031, China
    2. Department of Central Laboratory, Affiliated Hospital of Shandong Academy of Medical Sciences, Linyi Shandong 250031, China
  • Received:2018-02-23 Published:2019-02-26
  • Corresponding author: Huiyong Shi
  • About author:
    Corresponding author: Shi Huiyong, Email:
引用本文:

石会勇, 赵春红, 甄亚男, 霍守俊, 王若谷. 外周血SEPT9基因甲基化检测在结直肠癌筛查及术后随访中的意义分析[J]. 中华普外科手术学杂志(电子版), 2019, 13(01): 65-68.

Huiyong Shi, Chunhong Zhao, Yanan Zhen, Shoujun Huo, Ruogu Wang. Analysis of SEPT9 gene methylation in diagnosis and follow-up of colorectal cancer[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2019, 13(01): 65-68.

目的

探讨外周血SEPT9基因甲基化检测在结直肠癌筛查及随访中的应用。

方法

回顾性分析2014年10月至2015年12月接受结直肠癌筛查人群共计783例,其中确诊结直肠癌患者72例,非结直肠癌患者711例。对所有纳入患者进行外周血SEPT9甲基化检测和病理检查。以病理诊断为金标准,采用ROC曲线分析SEPT9阳性对结直肠癌的诊断价值,术后随访1年,观察外周血SEPT9基因甲基化和患者生存情况的关系。应用SPSS 23.0软件进行统计学分析,性别、年龄段、病变位置、TNM分期等资料以[例(%)]表示,比较采用卡方检验,以P<0.05为差异有统计学意义。

结果

结直肠癌患者SEPT9基因甲基化(70.8%)显著高于非结直肠癌患者(13.5%);SEPT9基因甲基化在TNM分期Ⅰ期、Ⅱ期、Ⅲ期及Ⅳ期结直肠癌患者的阳性率依次为:47.4%、 69.2%、 88.9%、 88.9%。ROC曲线分析显示,SEPT9的AUC=0.787,高于CA125和CA199(P<0.05),其诊断结直肠癌的灵敏度为86.5%,特异度为70.8%。术后随访1年发现,88.2%的SEPT9基因甲基化阳性患者在结直肠癌根治术后转为阴性,与SEPT9甲基化转阴性的患者相比较,SEPT9甲基化未转为阴性的患者预后较差。

结论

SEPT9基因甲基化检测可能作为评估结直肠癌风险和预后的一项重要检测指标。

Objective

To study the analysis of SEPT9 gene methylation in diagnosis and follow-up of colorectal cancer.

Methods

The clinical data of 783 cases of colorectal cancer screening in our hospital from October 2014 to December 2015 were analyzed. There were 72 patients diagnosed with colorectal cancer, 711 cases were excluded colorectal cancer. In there, all patients were performed by peripheral blood SEPT9 methylation detection and pathological examination. Pathological diagnosis was used as gold standard, with the ROC curve, the diagnostic value of SEPT9 positive for colorectal cancer was evaluated. After 1 years of follow-up, the SEPT9 gene methylation and the survival of the patients were observed. Statistical analysis were performed by using SPSS 23.0 software, the classification data such as sex, age, location of lesion, TNM stage and et al were presented as n(%), and examined by using Chi square test. A P<0.05 was considered as significant difference.

Results

The level of SEPT9 gene methylation of colorectal cancer patients was significant higher than non-colorectal cancer patients. The positive rate of SEPT9 gene methylation of colorectal cancer patients in stage Ⅰ, stage Ⅱ, stage Ⅲ and Ⅳ was 47.4%, 69.2%, 88.89%, 88.9% respectivly. ROC curve analysis showed that the SEPT9 was higher than that of CA125 and CA199 curve (P<0.05), the sensitivity and specificity of the diagnosis of colorectal cancer was 86.5% and 70.8%. After 1 year of follow-up, 88.2% of positive SEPT9 gene methylation patients turned to negative after colorectal cancer surgery, compared with this patients, the prognosis of patients whose SEPT9 methylation had not turned to negative had a poor prognosis.

Conclusion

SEPT9 gene methylation could be used as an important test indicator for the risk and prognosis of colorectal cancer.

图1 结直肠癌患者SEPT9基因甲基化检测
表1 783例筛查人群两组患者SEPT9、 CA125和CA199阳性率比较[例(%)]
表2 72例结直肠癌患者SEPT9基因甲基化病理因素比较[例(%)]
图2 783例患者SEPT9基因甲基化诊断结直肠癌的ROC曲线
表3 783例患者SEPT9、 CA125、 CA199的诊断效能
[1]
陈功,万德森.结直肠癌防治研究最新进展[J].广东医学,2016,37(22):3323-3328.
[2]
刘茉,王亚东,王贵齐,等.基于慢病管理的结直肠癌筛查模式初探[J].中华疾病控制杂志,2015,19(5):524-527.
[3]
李世拥,陈纲,杜峻峰,等.腹腔镜右半结肠癌根治术的临床疗效分析[J/CD].中华普外科手术学杂志:电子版,2015, 9(1):28-30.
[4]
蒋奕玫,赵任.肿瘤标志物在结直肠癌诊断中的作用[J].上海交通大学学报医学版,2015, 35(11):1734-1737.
[5]
Molnár B,Tóth K,Barták BK,et al.Plasma methylated septin 9: a colorectal cancer screening marker[J].Expert Rev Mol Diagn,2015,15(2):171-184.
[6]
Song L,Li Y.Chapter Four - SEPT9: A Specific Circulating Biomarker for Colorectal Cancer[J].Adv Clin Chem,2015,72(7):171-204.
[7]
Spiliotis ET,Kinoshita M,Nelson WJ.A mitotic septin scaffold required for Mammalian chromosome congression and segregation[J].Science,2005,307(5716):1781-1785.
[8]
Li Y,Song L,Gong Y,et al.Detection of colorectal cancer by DNA methylation biomarker SEPT9: past, present and future[J].Biomark Med,2014,8(5):755-769.
[9]
Payne SR.From discovery to the clinic: the novel DNA methylation biomarker (m)SEPT9 for the detection of colorectal cancer in blood[J].Epigenomics,2016,2(4):575-585.
[10]
Lofton-Day C,Model F,Devos T,et al.DNA methylation biomarkers for blood-based colorectal cancer screening[J].Clin Chem,2008,54(2):414-423.
[11]
Grützmann R,Molnar B,Pilarsky C,et al.Sensitive Detection of Colorectal Cancer in Peripheral Blood by Septin 9 DNA Methylation Assay[J].Plos One,2008,3(11):e3759.
[12]
Wasserkort R,Kalmar A,Valcz G,et al.Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island[J].BMC Cancer,2013,13(1):398-398.
[13]
Yan S,Liu Z,Yu S,et al.Diagnostic Value of Methylated SEPT9 for Colorectal Cancer Screening: A Meta-Analysis[J].Med Sci Monit,2016,22(9):3409-3418.
[14]
Kang Q,Jin P,Yang L,et al.Significance of SEPT9 gene methylation detection of plasma circulation DNA in colorectal cancer screening[J].Zhonghua Yi Xue Za Zhi,2014,94(48):3839-3841.
[15]
贺娜,吴开春.血浆甲基化septin9基因与结直肠癌相关性的研究进展[J].中华消化杂志,2015,35(5):358-360.
[16]
Johnson DA,Barclay RL,Mergener K,et al.Plasma SEPT9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study[J].Plos One,2014,9(6):e98238.
[1] 康夏, 田浩, 钱进, 高源, 缪洪明, 齐晓伟. 骨织素抑制破骨细胞分化改善肿瘤骨转移中骨溶解的机制研究[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 329-339.
[2] 李文琳, 羊玲, 邢凯慧, 陈彩华, 钟丽花, 张娅琴, 张薇. 脐动脉血血气分析联合振幅整合脑电图对新生儿窒息脑损伤的早期诊断价值分析[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 550-558.
[3] 王蓓蓓, 董启秀, 郗红燕, 于庆云, 张丽君, 式光. 早孕期孕妇药物流产失败的影响因素分析与构建相关预测模型及其对药物流产成功的预测价值[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 588-594.
[4] 陈絮, 詹玉茹, 王纯华. 孕妇ABO血型联合甲状腺功能检测对预测妊娠期糖尿病的临床价值[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 604-610.
[5] 代莉, 邓恢伟, 郭华静, 黄芙蓉. 术中持续输注艾司氯胺酮对腹腔镜结直肠癌手术患者术后睡眠质量的影响[J]. 中华普通外科学文献(电子版), 2023, 17(06): 408-412.
[6] 王得晨, 杨康, 杨自杰, 归明彬, 屈莲平, 张小凤, 高峰. 结直肠癌微卫星稳定状态和程序性死亡、吲哚胺2,3-双加氧酶关系的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(06): 462-465.
[7] 唐旭, 韩冰, 刘威, 陈茹星. 结直肠癌根治术后隐匿性肝转移危险因素分析及预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 16-20.
[8] 张生军, 赵阿静, 李守博, 郝祥宏, 刘敏丽. 高糖通过HGF/c-met通路促进结直肠癌侵袭和迁移的实验研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 21-24.
[9] 李婷, 张琳. 血清脂肪酸代谢物及维生素D水平与结直肠癌发生的关系研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 661-665.
[10] 常剑, 邱峰, 毛郁琪. 摄食抑制因子-1与腹腔镜结直肠癌根治术后肝转移的关系分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 502-505.
[11] 王晓燕, 肖佑, 肖戈, 王真权. 老年结直肠癌肺转移CT特征及高危因素研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 506-509.
[12] 倪文凯, 齐翀, 许小丹, 周燮程, 殷庆章, 蔡元坤. 结直肠癌患者术后发生延迟性肠麻痹的影响因素分析[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 484-489.
[13] 范小彧, 孙司正, 鄂一民, 喻春钊. 梗阻性左半结肠癌不同手术治疗方案的选择应用[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 500-504.
[14] 关旭, 王锡山. 基于外科与免疫视角思考结直肠癌区域淋巴结处理的功与过[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 448-452.
[15] 顾睿祈, 方洪生, 蔡国响. 循环肿瘤DNA检测在结直肠癌诊治中的应用与进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 453-459.
阅读次数
全文


摘要